Search clinical trials for: RO5503781

Total 14 results

Hoffmann-La Roche

Completed

A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia

Neoplasms

France, Canada, Netherlands, Korea, Republic of, Australia
Hoffmann-La Roche

Completed

A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors

Solid Tumors

United States, Canada
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
St. Jude Children's Research Hospital

Withdrawn

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Rhabdoid Tumor | CNS Tumor | Atypical Teratoid/Rhabdoid Tumor | Atypical Teratoid/Rhabdoid Tumor of CNS

United States
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Polycythemia Vera

United States, Canada, Italy, Australia
Canadian Forces Health Services Centre Ottawa

Active, not recruiting

Psychedelic Therapy for Wellness Studies Retrospectively

Well Aging

Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Hoffmann-La Roche

Terminated

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Non-Hodgkin's Lymphoma

United States, Australia, Korea, Republic of, Germany, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

Myelogenous Leukemia, Acute

United States, Korea, Republic of, Australia, United Kingdom, Canada, France, Italy
Hoffmann-La Roche

Terminated

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)

Breast Cancer

Italy, United States, Korea, Republic of, Canada, Czechia, Spain, Australia, Bulgaria, China, Finland, France, Greece, Poland, Portugal, Taiwan, Thailand, Turkey, Colombia, Bosnia and Herzegovina, Mexico, Peru, Romania, Russian Federation and more
Hoffmann-La Roche

Terminated

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Acute Myeloid Leukemia

Spain, United States, France, Australia, Italy
Hoffmann-La Roche

Completed

A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

Neoplasms

Canada, United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma | Loss of Chromosome 17p

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam

3

Subscribe